9 news items
Competitor Analysis: Evaluating Regeneron Pharmaceuticals And Competitors In Biotechnology Industry
REGN
4 Jun 24
profitability and growth potential.
Compared to its industry, the company has higher Earnings Before Interest, Taxes, Depreciation
MAIA Biotechnology Inc (MAIA) Stock Surges as Company Prepares to Present Promising Data at BIO International Convention
CRL
IQV
MAIA
31 May 24
a recommendation to buy or sell a security. It is solely informational, and you should not construe it as legal, tax, investment, financial, or other advice
Insights Into Regeneron Pharmaceuticals's Performance Versus Peers In Biotechnology Sector
REGN
17 May 24
Interest, Taxes, Depreciation, and Amortization (EBITDA) of $830 Million is 0.86x below the industry average, suggesting potential lower
Industry Comparison: Evaluating Regeneron Pharmaceuticals Against Competitors In Biotechnology Industry
REGN
2 May 24
Before Interest, Taxes, Depreciation, and Amortization (EBITDA) of $1.28 Billion, which is 1.03x above the industry average, indicating
Regeneron Reports First Quarter 2024 Financial and Operating Results
REGN
2 May 24
. In the first quarter of 2024, the Company's GAAP effective tax rate (ETR) was (3.0%), compared to 4.7% in the first quarter of 2023
vkl4c3q2vxnbegpdx1odn0kx4 zljw6
REGN
18 Apr 24
to generate profits, which could be attributed to various factors.
The company has lower Earnings Before Interest, Taxes, Depreciation
0mi877r ww8xif5yoznv8
ARGX
ATNM
MRNA
28 Mar 24
a recommendation to buy or sell a security. It is solely informational, and you should not construe it as legal, tax, investment, financial, or other advice
29k rlo8tq8vowo7mx9woly57zp8d7xb640tuz1
ARGX
ATNM
AZN
26 Mar 24
that no content published here constitutes a recommendation to buy or sell a security. It is solely informational, and you should not construe it as legal, tax
amwgcsekxdolue8slz0xrer
ARGX
ATNM
AZN
22 Mar 24
to buy or sell a security. It is solely informational, and you should not construe it as legal, tax, investment, financial, or other advice
- Prev
- 1
- Next